Anúncio
Anúncio
ANTX
AN2 Therapeutics, Inc. Common Stock
1.30
USDPatrocinado
+0.20
+18.64%
08 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
1.33
+0.02
+1.61%
Relatórios de Lucros ANTX
Rácio de surpresa positiva
ANTX separação 9 de 15 últimas estimativas.
60%
Próximo Relatório
Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.24
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/-22.58%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/-4.00%
AN2 Therapeutics, Inc. Common Stock earnings per share and revenue
On 12 de nov. de 2025, ANTX reported earnings of -0.31 USD per share (EPS) for Q3 25, missing the estimate of -0.22 USD, resulting in a -38.15% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.24% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an diminuir of -22.58% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were AN2 Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, AN2 Therapeutics, Inc. Common Stock reported EPS of -$0.31, missing estimates by -38.15%, and revenue of $0.00, 0% as expectations.
How did the market react to AN2 Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.24%, changed from $1.18 before the earnings release to $1.13 the day after.
When is AN2 Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 16 de mar. de 2026.
What are the forecasts for AN2 Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analistas, AN2 Therapeutics, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio